Atherosclerosis - A very deep dive into endothelial health genetic pathways for actionable insights

I’m continuing my deep dives into the genetic pathways to get actionable insights as the previous ones have been incredible precise and useful. This time I’m looking at endothelial health genetic pathways.

For context I got a stent at 61 even though my LDL has never really been very high and no MD ever told me to take a statin before that. I did one of those genetic polygenic scores that ranked me in the 99th percentile of having CAD which is probably as bad as it is possible but I didn’t got anything actionable from that so here it is.

Here is the general description of the pathways. I will put the finding about my own genome in a followup post.

Endothelial_Health_Genetic_Pathway_Reference V2.pdf (390.8 KB)

1 Like

As a teaser here is the summary of my own genome SNP analysis which is very bad indeed.
Note that it flags PSCK9 and PED5 as major issues. I’m already taking tadalafil 10mg but I guess I should also take some PCSK9 inhibitor.

Executive Summary

Analysis of 20 SNPs across nine functional categories reveals a genetic profile characterized by a clear convergence on NO signaling and the NO-receptor locus (GUCY1A3), combined with a major CAD locus hit (9p21 double heterozygous), a PCSK9 gain-of-function at the lipid-endothelium interface, and notable protective signals at CETP and IL6. The dominant theme is cGMP-pathway vulnerability with partially mitigating antioxidant and inflammatory profiles.

Primary Genetic Vulnerabilities (Homozygous Risk)

Homozygous risk at GUCY1A3 (rs13139571) — soluble guanylate cyclase α1, the NO receptor in vascular smooth muscle. Combined with rs7692387 heterozygous (the major CAD GWAS hit at this locus), this represents a two-hit impairment at the NO-receiving end of the vasodilation axis. Blunted cGMP response to NO independent of NO production.

Homozygous risk at PCSK9 (rs505151, Glu670Gly) — gain-of-function variant associated with higher LDL-C and elevated CHD risk. The Mendelian inverse of the protective R46L variant. Magnifies the need for aggressive LDL control.

Homozygous risk at PDE5A (rs3806808) — phosphodiesterase 5A variant that may alter cGMP degradation kinetics. Combined with the GUCY1A3 double-hit, this affects both cGMP generation and its turnover.

Homozygous risk at ICAM1 (rs5498, K469E) — intercellular adhesion molecule 1. Altered sICAM-1 kinetics; increased leukocyte-endothelial interaction.

Homozygous risk at XDH (rs206812) — xanthine oxidoreductase. A source of vascular superoxide and a determinant of urate/BP. Adds to the oxidative load side of the redox ledger.

Homozygous risk at SPR (rs1876487) — sepiapterin reductase, final step of de novo BH4 synthesis. Potentially reduces BH4 availability, increasing risk of eNOS uncoupling when combined with NOS3 rs1799983 het.

Major CAD Locus Finding

9p21 / CDKN2B-AS1 double heterozygous (rs10757278 and rs1333049) — the single strongest common CAD locus known. Two independent heterozygous signals at this locus confer approximately 1.25–1.5× elevated lifetime CAD risk, independent of lipids, blood pressure, and diabetes (Helgadottir et al., Science 2007; CARDIoGRAMplusC4D). The mechanism is thought to involve lncRNA-mediated regulation of vascular smooth muscle proliferation and senescence rather than a direct effect on NO signaling.

These are only the major ones.

Here is the full report so that people can look at the actionable info, the medications and supplements.
Endothelial_Health_Genetic_Report V2.pdf (408.8 KB)

Can you please share the prompts that you are using for these types of queries?

Sure. Here it is.
BTW the prompt refers to previous documents as a model for the structure so you can just provide the first doc I’ve already uploaded above.


I’d like a comprehensive genetic analysis of the SNPs related to [endothelial health]
following the same structure and depth as my prior reports (Homocysteine Regulation, Glucose Dysregulation, Glycation Pathways).

Phase 1: Research and Pathway Education

First, research the pathway using evidence-based sources only (peer-reviewed
journals, GWAS catalogs, OMIM, PubMed). Then walk me through:

  1. The biology of the pathway: what it does, why it matters, how it’s regulated
  2. The functional categories of genes involved (typically 6-10 categories)
  3. For each category, the key genes and their roles
  4. For each gene, the well-studied SNPs with:
    • rsID and common variant name (e.g., C677T, V158M)
    • Functional consequence of the variant
    • Cofactors required by the enzyme
    • GWAS evidence and effect size where available

Cite sources inline. Use a pathway diagram (visualizer) to anchor the explanation.

Stop here and wait for my confirmation before proceeding.

Phase 2: Generic Reference Document

After I confirm Phase 1, create the FIRST docx: a generic, shareable reference
document containing ONLY:

  • Pathway biology and mechanism explanation
  • Complete catalog of genes organized by functional category with making explicit or split by subcategories like “absorption / transport / activation”
  • For each gene: SNPs, variant names, functional interpretation, cofactors
  • Summary table mapping categories → genes → cofactors → supplement targets
  • Complete SNP lookup list (formatted as a clean reference table)
  • Bibliography / source notes

This document must contain ZERO references to:

  • My personal genome data
  • My medications or supplements
  • My prior reports or specific findings
  • Any “the patient” language

It should read as a standalone educational reference that I could share with
anyone (a doctor, a friend, a research collaborator) without exposing personal
health information. Title it: “[PATHWAY] Genetic Pathway Reference”

After creating this document, give me bcftools commands to look up all the SNPs
in my VCF file. Provide both an rsID-based query and a positional fallback
(GRCh38 coordinates) in case rsIDs aren’t annotated.

Stop here and wait for me to provide my genotype results.

Phase 3: Personalized Analysis Document

After I provide the bcftools output, create the SECOND docx: a comprehensive
personalized analysis following the EXACT structure of my prior reports:

  1. Title block with date, source, genome build
  2. Disclaimer
  3. Executive Summary with:
    • Primary genetic vulnerabilities (homozygous risk findings)
    • Secondary findings (heterozygous / moderate)
    • Genetically protected pathways (variants not found or protective)
  4. Detailed SNP Results by Functional Category
    • Color-coded genotype tables (homozygous risk = red, het = yellow,
      no risk = green, protective = blue, low quality = red with asterisk)
    • Each table followed by an italicized interpretation paragraph
    • Mark low-quality variants with asterisks and quality details
  5. Integrated Genetic Risk Profile (summary table with risk levels)
  6. Convergence Analysis: identify 2-4 functional bottlenecks where multiple
    variants compound each other. For each bottleneck:
    • Name the chain of variants
    • Explain the mechanism
    • State the clinical implication
  7. Current Management & Genetic Alignment
    • Read my medications-supplements.md file
    • Table of current supplements with doses and alignment commentary
      (HIGHLY FAVORABLE / FAVORABLE / NEUTRAL / CAUTION / MIXED)
    • Table of current medications with similar alignment commentary
    • Table of MISSING items (gaps) with suggested doses and priority levels
      (HIGH / MODERATE / LOW priority)
  8. Cross-references to my prior reports where biologically relevant
    (e.g., if this pathway intersects with glucose, glycation, or
    homocysteine findings, call those out explicitly)
  9. Suggested Monitoring Panel with rationale for each test

Style requirements (match my prior reports exactly):

  • Arial font, US Letter size
  • Heading 1 in dark blue (#1F3864), Heading 2 in medium blue
  • Color-coded cells for genotypes and risk levels
  • Striped row backgrounds in management tables (#F2F6FA alternating)
  • Tables with thin gray borders
  • Italic interpretation paragraphs after each SNP table
  • Footer with page numbers
  • Header with report title

For variants NOT found in the VCF, interpret as likely homozygous reference
(no risk alleles), noting that 60x WGS provides high confidence in detection.

Title this document: “endothelial health Genetic Report”

Important constraints throughout:

  • Use only evidence-based sources from main reputable journals
  • Cite GWAS p-values and effect sizes where available
  • Note when variants have controversial or mixed evidence
  • Flag low mapping quality (MQ < 40) or low depth (DP < 15) variants
  • Look for convergence patterns BETWEEN this pathway and my prior reports
  • Don’t make confident clinical recommendations; frame as “discuss with
    treating physician”
  • For supplement gaps, check whether my Momentous Multi might already cover
    them and flag for verification

After completing both documents, also create a brief ONE-PAGE summary card
(markdown, not docx) listing the top 10 actionable findings I should discuss
with my physician at my next appointment.

1 Like

Detailed genetic analysis may have some value, but I don’t think it’s particularly actionable for the great majority of people. For anyone who says their LDL has never been high, that’s not enough information. Current analysis now puts more value on additional details regarding lipoprotein status. One should additionally consider their numbers for TGs, HDL, ApoB, and Lp(a), with measurement units specified. Someone whose LDL is not particularly high, may have significant elevation of ApoB with a type B lipid distribution with excessive SD LDL particles, which are particularly atherogenic. Finally, we are now aware of the importance of hsCRP as an independent risk factor for CVDz, so inflammatory status should always be considered. I can’t change my genetics, but I can attempt to modify my lipid parameters, if I know what they are and take the appropriate action as regards diet, exercise, medication….

Indeed and that’s exactly the point of those deep dives.
For instance I have a PCSK9 homozygous gain of function variant associated with higher LDL-C and
higher CHD risk so a PCSK9 inhibitor is probably an optimal option.

I also have a PDE5A homozygous variant, which affects cGMP degradation. The
NO-to-vasodilation signal is compressed from both ends: less cGMP generated per unit NO
(GUCY1A3), and altered cGMP kinetics (PDE5A) so Tadalafil is directly relevant here.

Similarly for some other bad SNPs, I can find medications or supplements that target them.

From the deep dive in glucose regulation I know that I’m lacking a receptor for Metformin to work but that Imeglimin will work and that’s a really useful and actionable insight.

1 Like